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Simple Summary: Malignant pleural mesothelioma (MPM) is an incurable and aggressive malignancy
mainly caused by exposure to asbestos fibers. Survival outcomes following the standard of care
treatment, including chemotherapy and surgery, remain dismal. Targeted treatments are shortcomings
for MPM, as this tumor is driven primarily by a loss of tumor suppressor genes. In this study,
we explored the importance of proteins that have been shown to be dysregulated in MPM as a
consequence of tumor suppressor gene loss, CUL4A and CUL4B. We assessed their expression levels
and identified their correlation with clinical outcomes of MPM. We also aimed to test the efficacy
and mechanisms of the available treatments that target these proteins, pevonedistat using in vitro
and in vivo models. Our data suggested that CUL4B might serve as a treatment target for MPM and
revealed novel mechanism of pevonedistat in the MPM tumor microenvironment. This data may be
useful for understanding its efficacy in patients from clinical trials.
Abstract: Neurofibromatosis type 2 (NF2), the tumor suppressor frequently lost in malignant pleural
mesothelioma (MPM), suppresses tumorigenesis in part by inhibiting the Cullin4 ubiquitin ligase
(CUL4) complex in the nucleus. Here, we evaluated the importance of CUL4 in MPM progression and
tested the efficacy of cullin inhibition by pevonedistat, a small molecule inhibiting cullin neddylation.
CUL4 paralogs (CUL4A and CUL4B) were upregulated in MPM tumor specimens compared to
nonmalignant pleural tissues. High gene and protein expressions of CUL4B was associated with a
worse progression-free survival of MPM patients. Among 13 MPM cell lines tested, five (38%) were
highly sensitive to pevonedistat (half maximal inhibitory concentration of cell survival IC50 < 0.5 µM).
This remained true in a 3D spheroid culture. Pevonedistat treatment caused the accumulation of
CDT1 and p21 in both sensitive and resistant cell lines. However, the treatment induced S/G2 cell
cycle arrest and DNA rereplication predominantly in the sensitive cell lines. In an in vivo mouse
model, the pevonedistat treatment significantly prolonged the survival of mice bearing both sensitive
and resistant MPM tumors. Pevonedistat treatment reduced growth in sensitive tumors but increased
apoptosis in resistant tumors. The mechanism in the resistant tumor model may be mediated by
reduced macrophage infiltration, resulting from the suppression of macrophage chemotactic cytokines,
C-C motif chemokine ligand 2 (CCL2), expression in tumor cells.
Keywords: malignant pleural mesothelioma; NF2; ubiquitination; CUL4A; CUL4B; neddylation;
pevonedistat
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1. Introduction
Malignant pleural mesothelioma (MPM) arises from the malignant transformation of mesothelial
cells lining the thoracic cavity. MPM is a rare but aggressive tumor commonly associated with the
chronic inflammation of tissues exposed to asbestos fibers. The current standard first-line chemotherapy
includes cis- or carboplatin and pemetrexed that holds only a 41% response rate [1]. Alternative
treatment options are shortcomings for a tumor mainly driven by the loss of tumor-suppressor
genes like MPM due to the lack of targetable oncogenic drivers. One of the most frequently lost
tumor-suppressor gene in MPM is neurofibromatosis type 2 (NF2) encoding the protein Merlin. NF2 is
mutated in 19% of MPM, and the chromosomal region 22q containing this gene is commonly lost in
MPM tumor tissues [2,3].
Merlin, a well-known tumor-suppressor protein, has been shown to regulate several oncogenic
pathways [4], and its activity is tightly regulated by phosphorylation and localization [5]. A study by
Li et al. suggested that only the unphosphorylated closed conformation of Merlin enters the nucleus
to prevent tumorigenesis by inhibiting the Cullin4-RING E3 ubiquitin ligase complex (CRL4) [6].
Recently, our own research showed that low nuclear Merlin expression following chemotherapy was
associated with worse survival outcomes of MPM patients [7]. Thus, CRL4 may serve as a potential
pathway target for the treatment of MPM.
Cullin4 (CUL4) is a member of the cullin-RING ligase protein family. Cullins provide a core
scaffold for ubiquitin ligase complex formation to catalyze the ubiquitination of target proteins for
proteasomal degradation or activity changes [8,9]. Two CUL4 paralogs, CUL4A and CUL4B, share 82%
similarity in protein sequences and have been shown to facilitate nucleotide excision repair and cell
cycle progression [9]. Recent evidence revealed that the CUL4A gene (13q34) was amplified in MPM
cell lines and overexpressed in 64% of MPM tumors [10]. In addition, CUL4A has also been shown to
be amplified in breast cancer and was associated with a shorter overall and disease-free survival [8].
A study by Yang et al. using cre-inducible CUL4A expression demonstrated that CUL4A overexpression
in the lung induced the development of adenocarcinoma in a mouse model [11]. Although CUL4B has
been shown to be associated with the progression and tumorigenesis of other cancers, there is, so far,
no study assessing whether CUL4B is important for MPM progression. In colon cancer, patients with
CUL4B-positive tumors had a higher recurrence rate and shorter survival time compared to patients
with CUL4B-negative tumors [12]. Transgenic mice overexpressing CUL4B in the liver exhibited
increased hepatocyte proliferation and accelerated tumor development after chemical exposure [13].
Clear roles of CUL4 and other members of the cullin family in the regulation of cell growth
and their association with the progression of various cancers suggested them as an attractive target
molecule for the treatment of cancer. The conjugation of a ubiquitin-like protein, NEDD8 (neural
precursor cell expressed, developmentally downregulated 8), stimulates the activity of cullins by
inducing conformational changes to facilitate a ubiquitin transfer [14]. A small molecule MLN-4924
(pevonedistat) inhibits cullins by inhibiting protein neddylation. By binding covalently to the active
site of the NEDD8-activating enzyme (NAE), the pevonedistat-NAE adduct cannot be processed any
further in the NEDD8 pathway [15]. Pevonedistat demonstrated antineoplastic activity by inducing
the apoptosis and scenence of cancer cells [16]. Pevonedistat has entered several Phase I and II clinical
trials for hematologic malignancies and solid tumors, including MPM.
We hypothesized that altered ubiquitination events resulting from Merlin loss or CUL4A/B gain
of function is one of the drivers of MPM progression. In this study, we assessed the importance of both
CUL4 paralogs in MPM and tested whether the pharmacological inhibition of cullins by pevonedistat
is effective for MPM. Although pevonedistat has been tested in MPM in the context of NF2 loss and
now is being tested in clinical trials for MPM, there has not been a mechanistic detail explaining the
treatment efficacy in vivo and possible effects on the tumor microenvironment. Here, we employed
a panel of MPM cell lines to assess the efficacy and mechanisms of pevonedistat in in vitro 2D and
3D models prior to confirming in vivo using a mouse model in which the tumors develop on the
mesothelial tissues of the peritoneal cavity, providing a more relevant tumor microenvironment.
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We also assessed the long-term outcome of the pevonedistat treatment by monitoring the overall
survival after the treatment.
2. Results
2.1. CUL4A and CUL4B Expression Was Elevated in a Subset of MPM Patients, and High CUL4B Expression
Was Associated with a Poor Outcome
We assessed the gene expression of CUL4A and CUL4B in 94 tumor tissues collected from MPM
patients at diagnosis, surgery or relapse by quantitative real-time PCR (qPCR). Non-MPM samples are
tissue samples collected from patients with chronic inflammation of the pleura for whom the final
diagnosis was negative for MPM. CUL4A, and, more significantly, CUL4B expression were elevated in
a subset of MPM tumors from all time points (Figure 1a). We did not find any correlation between
CUL4A and CUL4B expression with the progression-free survival (PFS) and overall survival (OS) of
patients in this cohort (data not shown), most probably due to the small sample size. Gene expression
data from the publicly available TCGA database (MESO dataset) showed that a high CUL4B gene
expression was associated with a shorter disease-free survival of patients (Figure 1b), while there
was no association between the CUL4A expression with survival outcomes (data not shown) [17].
Accordingly, the protein expression by immunohistochemistry on a tissue microarray of our MPM
patient cohort showed that high CUL4B protein expression was associated with a short PFS of the
patients (Figure 1c). In contrast, on the protein expression level, we found that high cytoplasmic
CUL4A expression was associated longer PFS (p = 0.01). The details of the patient cohort for the tissue
microarray are provided in Table S1. There were no correlations between the CUL4A and CUL4B
protein expressions with histological subtypes of MPM.
Figure 1. Significance of CUL4A and CUL4B expressions in malignant pleural mesothelioma (MPM).
(a) qPCR analysis showing the upregulation of CUL4A and CUL4B gene expressions in a subset
of MPM tissues collected at various time points (diagnosis (n = 34), surgery (n =50) and relapse
(n = 10)) compared to non-MPM tissues (n = 18). We used β-actin as a reference gene and the median
threshold cycle difference between CUL4A or CUL4B compared to β-actin (∆Ct) of the non-MPM group
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as a reference value for relative quantification by the 2−∆∆Ct method. The bars show medians with
interquartile ranges. Mann Whitney test, ns, not significant; * p < 0.05, ** p < 0.001 and *** p < 0.0001.
(b) Gene expression dataset from TCGA showing an association between high CUL4B expression with
shorter disease-free survival (n = 82). (c) Example of immunohistochemical staining of CUL4B showing
protein localization predominantly in the nucleus (N); cytoplasmic (C) expression is present but at a
lower extent. High protein expression of CUL4B in both nucleus and cytoplasm in this patient cohort
(n = 143) is associated with shorter PFS. The data were dichotomized according to the median gene
or protein expression of the patient cohort for Kaplan-Meier curves. We used a log-rank test for the
comparison of survival differences. PFS, progression-free survival and CI, confidence interval.
2.2. CU4LA and CUL4B Are Overexpressed in MPM Cell Lines, and a Subset of Them Were Susceptible to the
Inhibition of NEDD8 Activating Enzyme (NAE) by Pevonedistat
We employed a panel of 13 MPM cell lines and two nonmalignant mesothelial cells (Met5A
and SDM104 [18]) for an assessment of MPM sensitivity and response to pevonedistat treatment.
While nonmalignant mesothelial cells are relatively resistant to the treatment ((half maximal inhibitory
concentration of cell survival (IC50), 2.4 and 2.7 µM for Met5A and SDM104, respectively), a subset
(n = 5, 38%) of MPM cell lines are very sensitive to the treatment with pevonedistat (IC50 < 0.5 µM)
(Figure 2a and Table S2). Examples of IC50 curves are provided in Figure S1. qPCR analysis showed
that 67% of MPM cell lines overexpressed CUL4A (up to ~two-fold), while all overexpressed CUL4B
(up to ~six-fold) compared to SDM104 (Figure 2b). A protein expression analysis showed that 92% of
the MPM cell lines overexpressed the CUL4A protein at a much higher extent compared to the gene
expression (up to ~39-fold, Figure 2c), while 75% overexpressed CUL4B with a similar extent compared
to the gene expression (up to ~10.2-fold, Figure 2d). There was a significant positive correlation
between CUL4B mRNA (Figure 2b) and protein levels of the untreated condition shown in Figure 2d
(r = 0.57, p = 0.04), while there was no positive correlation for CUL4A. The Western blot analysis shows
that 0.6-µM pevonedistat efficiently inhibited CUL4A and CUL4B neddylation (upper bands) in most
of the cell lines (Figure 2c,d). There was no correlation between CUL4A and CUL4B expression with
the sensitivity to pevonedistat.
Figure 2. In vitro response of MPM cell lines to pevonedistat. (a) IC50 showing the pevonedistat
concentration (µM) required for the inhibition of 50% cell survival after 3 days of drug exposure
(3-(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide (MTT) assay). The graph depicts the mean
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IC50 from at least two independent experiments from each cell line. (b) Gene expressions of CUL4A
and CUL4B in MPM cell lines normalized to the expression of the nonmalignant mesothelial cell
line SDM104. (c,d) Western blot analysis showing protein expressions of CUL4A and CUL4B in
MPM cell lines and nonmalignant mesothelial cell lines (Met5A and SDM104). The upper band (see
arrows) of CUL4A and CUL4B represent the neddylated form of both proteins. Treatment with 0.6-µM
pevonedistat for 24 h sufficiently inhibited the neddylation of CUL4A and CUL4B in most of the cell
lines. The number above each line of the blots represents the protein expression (ratio densitometry
of the bands normalized with β-actin) relative to untreated SDM104. Underlined are the cell lines
sensitive to the neural precursor cell expressed, developmentally downregulated (NEDD) inhibition
by pevonedistat.
2.3. Increased Accumulation of Cells with DNA Rereplication in Pevonedistat-Sensitive Cell Lines
We next investigated the effect of pevonedistat treatment on the cell cycle. We observed increased
numbers of cells in the S and G2/M phases or cells containing >4N DNA in all the cell lines tested
(Figures S2 and 3a). This is, however, more pronounced in sensitive cell lines (Mero-82, MSTO211H
and ONE58). An increased number of cells in the sub-G1 population was only detected in the sensitive
MSTO211H cells after 24-h treatment (Figure S2). We therefore stained the cells with phospho-histone
H3 (ser10) (pH3) antibody to test whether the >4N population enters mitosis. The staining revealed
that >4N cells are negative for pH3 (Figure 3a), suggesting DNA rereplication in this cell population.
These data suggested that the effects of pevonedistat in sensitive cell lines is mediated primarily through
cell cycle arrest and increased DNA rereplication. These are known effects of pevonedistat mediated
by an accumulation of chromatin licensing and DNA replication factor 1, CDT1 and cyclin-dependent
kinase inhibitor, p21 [19,20]. CUL1 and CUL4 are known to involve in the degradation of CDT1 and p21
during cell cycle progression. The Western blot analysis showed increased CDT1 and p21 accumulation
in all cell lines, and there was no difference in the extent of CDT1 and p21 accumulation comparing
sensitive and resistant cell lines (Figure 3b,c). All cell lines showed reduced proliferation with 0.3-µM
pevonedistat (according to pH3 staining), but the growth of ACC-Meso-1 was affected starting from
1.2-µM pevonedistat (Figure 3b). Only the MSTO211H cell line showed increased apoptosis (based on
cleaved caspase-3 (Cl.C3) staining) following the treatment. Pevonedistat inhibited CUL4A and CUL4B
neddylation (upper bands) effectively in both sensitive (Mero-82 and MSTO211H) and resistant cell
lines (Met5A and ACC-Meso-1) (Figure 3b). In conclusion, although pevonedistat efficiently inhibited
CUL4 neddylation and the degradation of CDT1 and p21 in both sensitive and resistant cell lines,
the extent of DNA replication is more pronounced in the sensitive cell lines.
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Figure 3. Effects of pevonedistat treatment on cell cycle progression, p21 and CDT1 accumulation.
(a) Cell cycle analysis by double staining with (propidium iodide) PI and pH3 showing an accumulation
of cells in the S or G2 phase of the cell cycle predominantly in sensitive cells (Mero-82, MSTO211H
and ONE58) treated with 0.3-µM pevonedistat for 24 h compared to control (treated only with
dimethylsulfoxide (DMSO)). We noted a drastically increased accumulation of cells containing >4N
DNA after the treatment, predominantly in the sensitive cell lines, without increased accumulation of
cells undergoing mitosis (pH3+, circles). (b) Cells were treated with an increasing concentration of
pevonedistat for 24 h and subjected to Western blot analysis for the indicated proteins. Number above
each line of the blots represents protein expressions (ratio densitometry of the bands normalized
with β-actin) relative to no pevonedistat treatment. Arrows indicate neddylated CUL4A or CUL4B.
(c) A panel of MPM cell lines treated with DMSO or 0.6-µM pevonedistat for 24 h shows an accumulation
of CDT1 and p21 in both sensitive (underlined) and resistant cell lines. Number above each line of the
blots represents protein expressions (ratio densitometry of the bands normalized with β-actin) relative
to no pevonedistat treatment.
2.4. Three-Dimentional Culture Confirmed Differential Sensitivity of MPM Cell Lines to Pevonedistat
Cancer cells grown in three-dimensional (3D) are shown to better recapitulate the drug resistance
observed in patients than 2D cell culture experiments. Therefore, we selected four cell lines (resistant
ACC-Meso-1, nonmalignant mesothelial cell Met5A and sensitive cell lines Mero-82 and MSTO211H)
to confirm their sensitivity to pevonedistat in 3D culture. While the IC50 of pevonedistat was reduced
in 3D culture of Met5A (IC50 2D vs. 3D culture; 2.8 vs. 1.5 µM), all MPM cell lines showed an
increased IC50 of at least five times compared to 2D culture (IC50 2D vs. 3D culture; ACC-Meso-1 1.4
vs. >2.5 µM, Mero-82 0.12 vs. 0.7 µM and MSTO211H 0.06 vs. 0.4 µM). Similar to the results obtained
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from the 2D culture, these cells still exhibited differential sensitivity to pevonedistat when measured
by spheroid growth (Figure 4a) or cell survival at end of the treatment (Figure 4b). Treatment with
0.6-µM pevonedistat induced cell death and the dissociation of cells from spheroids in Mero-82 and
MSTO211H, while it only moderately affected Met5A growth without visible cell death and showed
no effect on ACC-Meso-1 (Figure 4c). We also treated spheroids with cisplatin, a standard of care
chemotherapy for MPM, to test whether the drug resistance is specific for pevonedistat or a general
characteristic of each cell line. There is a switch in the resistant pattern, with pevonedistat-sensitive
Mero-82 being relatively resistant to cisplatin while pevonedistat-resistant Met5A are sensitive to the
treatment with cisplatin (Figures S3 and S4). We therefore concluded that this is rather a drug-specific
resistance mechanism. We then analyzed the proliferation (pH3) and apoptosis (Cl.C3), CDT1 and
p21 levels in ACC-Meso-1 and MSTO211H spheroids (Figure 4d,e). We clearly observed a reduced
proliferation of MSTO211H as early as six h after the treatment, while ACC-Meso-1 was not affected
up to 24 h after the treatment. Treatment-induced apoptosis can be observed in MSTO211H at a 24 h
post-treatment start. Similar to 2D culture, CDT1 and p21 accumulation was detected in both cell lines.
Figure 4. Response of MPM cell lines grown in 3D culture to pevonedistat. (a) Cells grown in
multicellular spheroids were treated on day 4 and day 7 after seeding with the indicated increasing
concentration of pevonedistat (µM). To monitor the drug efficacy, we measured the spheroid volume
on days 4, 7, 9 and 11. The graphs were plotted as a percentage of the sphere volume compared to day
4. Pevonedistat effectively inhibited the growth of Met5A, Mero-82 and MSTO211H without affecting
ACC-Meso-1 at any concentration tested. (b) The IC50 of pevonedistat in the inhibition of the spheroid
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cell survival, measured by the acid phosphatase (APH) assay on day 11, confirmed that Mero-82 and
MSTO211H are sensitive to the treatment while ACC-Meso-1 is resistant. (c) Representative images of
spheroids treated with 0.6-µM pevonedistat. The presence of dead cells was visible in Mero-82 and
MSTO211H. Red lines are the measurements of the spheroid diameters. (d) Immunofluorescent staining
of pH3, cleaved caspase-3 (Cl.C3), CDT1 (green) and immunohistochemical staining of p21 (brown) in
spheroids after 24 h treatment with 0.6-µM pevonedistat. Fluorescent stainings were co-stained with
DNA staining with 4′,6-Diamidino-2-Phenylindole (DAPI, blue) and pan-cytokeratin (red). DAPI signal
was omitted from CDT1 staining for better visualization of the CDT1 signal. Scale bars represent
100 µm. (e) Quantification of the staining showed the accumulation of CDT1 and p21 in both cell lines
after treatment, but only affected the proliferation (pH3) and induced apoptosis (Cl.C3) in MSTO211H.
2.5. Efficacy of Pevonedistat In Vivo May Also Be Mediated by the Modulation of the Tumor Microenvironment
in the Immune-Deficient Model
To further confirm the treatment efficacy and mechanism of action, we conducted in vivo
experiments by selecting resistant and sensitive models. Among all cell lines tested, resistant ACC-
Meso-1 and sensitive MSTO211H are tumorigenic in immunodeficient mice. We treated mice bearing
tumors with pevonedistat with the dosage shown to be effective in other cancer models (50 mg/kg
twice-daily (BID) applying a cycle of five days on and five days off the drug (Figure 5a)) [20]. MSTO211H
tumor-bearing mice lost weight when treated with 50-mg/kg pevonedistat. Nevertheless, after the
adaptation by receiving an increasing dosage during the first cycle, MSTO211H-bearing mice adapted to
the treatment and tolerated the second cycle at 50-mg/kg BID (Figure S5). By monitoring animals closely
daily, we used the overall survival as the readout for treatment efficacy. As expected, pevonedistat
treatment prolonged the survival of MSTO211H-bearing mice by 13 days. Surprisingly, there was also a
survival benefit of the treatment for ACC-Meso-1-bearing mice by 32.5 days (Figure 5b). The analysis of
pevonedistat-treated tumor tissues showed a significant increase in p21 and CDT1 accumulation only
in ACC-Meso-1-bearing mice (Figure 5c–e). Reduced tumor cell proliferation (pH3) was detected only
in MSTO211H- but not ACC-Meso-1-bearing mice (Figure 5c,d). Surprisingly, we detected significantly
increased apoptosis in an ACC-Meso-1-derived tumor (Figure 5c,d). ACC-Meso-1 is very resistant
to pevonedistat and never underwent apoptosis, even with a high concentration of pevonedistat in
2D and 3D in-vitro models. We reasoned that there may be an effect of the treatment on the tumor
microenvironment that induced apoptosis of the ACC-Meso-1 tumor in vivo. Thus, we analyzed
cells associated with the tumor microenvironment, including mouse macrophage (F4/80+) and vessel
formation (CD31+) that may explain the efficacy of pevonedistat in the ACC-Meso-1 model. At the
baseline, ACC-Meso-1 tumors had a drastically higher macrophage infiltration (Figure 5c,e) compared to
MSTO211H tumors. The treatment significantly reduced the numbers of tumor-associated macrophages
in ACC-Meso-1 tumors, while it showed no effect on the MSTO211H tumors. There was no effect on
the blood vessel formation in both tumor models at this time point (Figure 5c,e).
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Figure 5. Efficacy and mechanisms of pevonedistat in an in vivo model. (a) Scheme depicting
the schedule for tumor implantation and pevonedistat treatment cycles for the mouse model.
(b) Kaplan-Meier plots showing significant differences in the overall survival (days) between the
vehicle and pevonedistat-treated mice bearing an ACC-Meso-1 tumor (left) and MSTO211H tumor
(right). (c) Comparison of tumor growth (pH3+), apoptosis (cleaved caspase 3, Cl.C3), CDT1 intensity,
p21 H-score, mouse macrophage recruitment (F4/80+ cells per tumor area) and mouse vessel formation
(CD31+ group of cells with visible lumen per tumor area) between vehicle-treated (filled circles) and
pevonedistat-treated mice (filled squares). # not significant; * p < 0.05, ** p < 0.001, (d) Representative
images of immunofluorescent staining for the indicated proteins with a green signal. They were
co-stained with DAPI (blue) and pan-cytokeratin (yellow or red). The DAPI signal was omitted from
CDT1 staining for a better visualization of the CDT1 signal. (e) Immunohistochemical staining of the
indicated markers and counterstained with hematoxylin (blue). Scale bars represent 100 µm.
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An effect of pevonedistat on tumor-associated macrophage recruitment was shown in the lung
cancer metastasis model, and the mechanism was mediated by a reduced expression of a macrophage
chemotactic cytokine, C-C motif chemokine ligand 2 (CCL2), in tumor cells [21]. We therefore used
mouse and human-specific primers to assess the expression of CCL2 in tumor tissues and found
that the ACC-Meso-1 tumor expressed much higher levels of CCL2 at the baseline (approximately
16,000-fold higher than MSTO211H) (Figure 6a). The treatment significantly suppressed human
CCL2 expression but had no effect on mouse CCL2 expression in the ACC-Meso-1 model (Figure 6b).
There was no effect of the treatment on mouse CCL2 expression in the MSTO211H model. Although
not significant, there seemed to be an increased expression of human CCL2 in the MSTO211H model
(Figure 6b). To confirm this finding, we tested in vitro and included also two additional MPM cell
lines in the analysis. The baseline expression of CCL2 was extremely different among those cell lines,
being ACC-Meso-1 and ONE58 expressed high levels of CCL2 while Mero-82 and MSTO211H expressed
very low-to-undetectable levels (Figure 6a). In agreement with the in vivo findings, an in vitro treatment
with pevonedistat caused the downregulation of CCL2 in ACC-Meso-1 and ONE58. Interestingly,
the opposite effect was detected in the Mero-82 and MSTO211H cell lines expressing low baseline
levels of CCL2 (Figure 6c).
Figure 6. Effect of pevonedistat treatment on the expression of CCL2. (a) Comparison of the baseline
expression levels of CCL2 in four different MPM cell lines in vitro. Lower Ct is equivalent to a higher
expression. (b) qPCR analysis using mouse and human-specific CCL2 primers (using human-specific
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β-actin and mouse-specific β-2-microglobulin as a reference gene) showing a significant reduction
of human CCL2 in the ACC-Meso-1 tumor treated with pevonedistat. (c) Change in the expression
of human CCL2 in vitro after pevonedistat treatment in MPM cell lines. (d) Scheme illustrating the
rationale and findings of our current study. CUL4A and CUL4B are shown to be regulated by Merlin
dysfunction; here, we sought to investigate the importance of CUL4A and CUL4B expressions in
MPM progression and tested the efficacy of pevonedistat, a small molecule inhibiting cullins via
protein neddylation. We observed that a high CUL4B expression was associated with the worst clinical
outcome. The treatment of MPM cells with pevonedistat resulted in an accumulation of CDT1 and p21,
known targets of CUL4 and CUL1, leading to cell cycle arrest. Reduced nuclear factor- κB (NF-κB)
pathway resulting from CUL1 inhibition caused a reduced CCL2 expression in tumor cells and reduced
macrophage infiltration in tumors. Via an unknown mechanism, a reduced macrophage infiltration
may result in more tumor cell death. It is important to note that CUL4A and CUL4B are shown to
regulate several ubiquitination targets; thus, these targets may be important for MPM progression,
and this remains to be investigated. In addition to cullins, pevonedistat also can affect some other
proteins that are also regulated by neddylation. # not significant; * p < 0.05, Ct, threshold cycle and ND,
not done.
3. Discussion
Our results show that, in addition to being deregulated by NF2 loss, a high expression of CUL4B
ubiquitin ligase may be among the driving factors for MPM progression. Targeting cullins by the
inhibition of protein neddylation is effective in 38% of MPM cell lines, while nonmalignant mesothelial
cell lines are relatively resistant. Our data suggest that CUL4B may serve as an additional treatment
target, and the inhibition of cullin activity using an inhibitor of protein neddylation may be efficacious
for the treatment of MPM. We discovered that the pevonedistat treatment depleted tumor-associated
macrophage infiltration (Figure 6d), which may be an additional favorable effect of pevonedistat for
the treatment of cancers.
We report here a significantly increased gene expression of CUL4A and, more significantly,
CUL4B in a subset of patients with MPM compared to a population with an inflammatory disease of the
pleura. Using publicly available data from TCGA, a high gene expression of CUL4B is associated with
a worse disease-free survival of the patients in this cohort. Accordingly, our data on protein expression
showed a significant association of CUL4B overexpression with worse clinical outcomes in MPM
patients (Figure 6d). To our knowledge, this is the first report on an importance of CUL4B in MPM.
Although sharing several similar functions with CUL4A, CUL4B harbors additional nuclear localization
signals in the extended N-terminus. While CUL4B is strongly localized in the nucleus, CUL4A is
mainly localized in the cytoplasm. CUL4B was shown to have unique roles in the nucleus, including
histone modification and the epigenetic regulation of various target genes [22–24]. Thus, it can be
hypothesized that they also possess independent cellular functions and, therefore, possess distinct
roles in MPM.
Using our cell line panel, we demonstrated that there was no correlation between gene and
protein levels for CUL4A. This suggests that the expression of CUL4A in MPM is regulated by
posttranslational modifications, in addition to the previously reported chromosomal gain [10]. It is still
unknown why CUL4B is upregulated in MPM. Mutations of CUL4B located on chromosome Xq24 are
associated with X-linked mental retardation syndrome, but its mutation has not been yet reported in
cancers, including MPM. A recurring gain of this chromosomal region has also not been reported in
MPM [25]. CUL4B has been shown to be regulated on the transcriptional level. A study in osteosarcoma
identified tumor-suppressor miR-300 as a negative regulator for CUL4B expression [26]. Additionally,
CUL4B expression was negatively regulated by miR-101-3p in lung cancer [27]. Although using a
small-number cohort, miR-101-3p was shown to be downregulated in MPM compared to normal
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tissues [28]. Thus, it can be hypothesized that the upregulation of CUL4B in MPM is, in part, modulated
by the alteration of miRNA levels and remains to be investigated.
There is a broad range of sensitivity of MPM cell lines in vitro to pevonedistat (IC50 ranging between
0.09–14.3 µM). This wide range of response has also been reported in a panel of melanoma and MPM
cell lines [29,30]. It seems that the primary immediate effects of the pevonedistat treatment are caused
by CDT1 accumulation, causing DNA rereplication and cell cycle arrest. Surprisingly, the treatment
induced CDT1 accumulation in both sensitive and resistant cell lines, with no preferentiality towards
the sensitive cell lines. Thus, there are other determining factors for the susceptibility of cells to
CDT1 accumulation. One possible mechanism is the p53 pathway, as it has been shown that cell lines
with p53 mutations are more susceptible to DNA rereplication compared to p53 wildtype after CDT1
overexpression [31]. p53 signaling was shown to be among the most significantly altered pathways in
MPM [2]. p53 is mutated in about 8% of MPM patients [2] and thought to be a driver of the near-haploid
subtype of MPM [25].
ACC-Meso-1 cells are very resistant to pevonedistat and only showed reduced proliferation after
treatment with high concentrations in the 2D and 3D cultures. Nevertheless, in vivo, we observed
increased apoptosis following the treatment without a growth delay. By observing cells associated
with the tumor microenvironment, we found a strong reduction of the number of tumor-associated
macrophages after pevonedistat treatment, which might be one of the reasons for the tumor growth delay
detected in this model. This is in-line with the study using a lung cancer metastasis immunocompetent
model that showed also reduced tumor-associated macrophages after pevonedistat treatment and,
therefore, a reduced metastasis potential of tumor cells [21]. In the aforementioned immunocompetent
model, it was shown that neddylation was important for monocyte chemotaxis to the tumor area,
where they differentiated into tumor-associated macrophages, and this was accompanied by an
increased number of tumor-infiltrating CD8+ T-cells. A reduced macrophage recruitment was
mediated by a reduced chemotaxis factor CCL2 production of tumor cells resulting from a nuclear
factor- κB (NF-κB) pathway blockade mediated by CUL1 inhibition. In our study, using human and
mouse-specific primers, we also demonstrated reduced human CCL2 but not mouse CCL2 expression
in vivo following the treatment with pevonedistat. Tumor-associated macrophages have been shown
to play various roles in supporting tumor progression, such as promoting angiogenesis and the
suppression of antitumor immunity [32]. Macrophages are abundantly present in MPM tumors, and it
has been shown that the number of tumor-associated macrophages negatively correlates with the
survival of patients with MPM sarcomatoid histology, supporting the tumor-promoting function of
macrophages in MPM [33,34]. Moreover, the levels of CCL2 are elevated in the MPM pleural effusion
on MPM patients compared to benign tissues [35], and CCL2 levels in the serum were elevated in
late-stage MPM patients [36], suggesting their importance in MPM progression. Thus, the inhibition of
CCL2 expression by pevonedistat may provide an additional benefit for MPM treatment, in addition to
targeting only tumor cells.
Our investigation revealed the opposite effect of the treatment on the cell lines expressing low
baseline levels of CCL2. The transcription of CCL2 was shown to be mainly dependent on the activity
of NF-κB [37]; it can be speculated that NF-κB may be less active in these cell lines. One possible
explanation of the increased CCL2 expression in these cells may be from an upregulation of exogenous
stimuli. Nevertheless, the extent of increased CCL2 expression did not affect macrophage recruitment
in this experimental model.
In contrast to our in vitro findings, no increased apoptosis was detected in the MSTO211H
in vivo model but only a suppression of tumor growth. MSTO211H formed aggressive fast-growing
tumor nodules. Thus, due to the large-growing tumor volume, the drug may be poorly diffused
into tumor nodules and cause only reduced proliferation in vivo. There is no effect of the treatment
on tumor-associated macrophages in this model; this might be explained by the fact that there was
much less tumor-associated macrophage recruitment in MSTO211H compared to ACC-Meso-1 tumors,
which corresponded to a low baseline expression of CCL2 in MSTO211H in vivo and in vitro.
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Since our mouse model lacks both functional T cells and B cells, it can be assumed that the effects
on tumor growth we have seen here are purely mediated by macrophage depletion. Tumor-suppressing
effects of pevonedistat may be more pronounced when functional T cells are present, and this remains
to be investigated.
4. Materials and Methods
4.1. MPM Tissue Microarrays (TMAs)
Tumor samples from 190 MPM patients were collected between 1999 and 2009. Patient’s characteristics
and treatment are described in Table S1. The study was approved, and a waiver of consent was granted
by the Ethical Committee Zürich (StV 29-2009 and EK-ZH 2012-0094).
4.2. Immunohistochemical Staining and Quantification for Protein Expression
Two-micrometer-TMA or tissue sections were deparaffinized and rehydrated. The staining for
CUL4A (LSBio, LS-B360, Seattle, WA, USA), CUL4B (Sigma, HPA HPA011880, Buchs, Switzerland),
p21 (Abcam, ab109199, Cambridge, UK), F4/80 (BMA Biomedicals, Augst, Switzerland) and CD31
(Abcam, ab28364, Cambridge, UK) was performed with a Dako Autostainer Link48 Instrument (Dako
Denmark A/S) according to the manufacture’s instructions. Antigen retrieval were achieved using
target retrieval solution pH 6 (Dako, K8005, Agilent Dako, Basel, Switzerland) for CUL4A and F4/80
and pH 9 (Dako, K8004, Agilent Dako, Basel, Switzerland) for CUL4B, CD31 and p21. We used a
visualization system consisting of the Dako EnVision™ rabbit/HRP/DAB system and counterstained
with hematoxylin. CUL4B antibody was developed and validated by the Human Protein Atlas
(HPA) project. We tested the specificity of immunohistochemical staining of the CUL4A antibody
using cell blocks from Met5A (low CUL4A expression) and Mero-82 (high CUL4A expression) and
observed a concordance between protein expressions tested by Western blotting (Figure 2c) and
immunohistochemical staining (Figure S6). Immunohistochemical staining score for TMAs (H-score)
from scanned images was obtained by a multiplication of intensity (0–3) with the staining frequency
(0–1) [7] in a blind fashion. M.M., J.K. and V.O. conducted CUL4A and CUL4B scoring on TMAs. M.M
evaluated p21 from the in vivo experiment using a modified H-scoring system, while the intensity
was scored as for TMAs (0–3); the frequency of cells with each staining intensity was estimated as an
actual % of the total cells (1–100%). Total H-score (ranging from 0–400) is the sum of each staining
intensity multiply by their frequency. Numbers of F4/80-positive cells and blood vessels (CD31+) were
normalized with the tumor area (mm2).
4.3. Tissue Samples for RNA Extraction
Tissue samples from 75 MPM patients and 18 patients with inflammatory disease of the pleura
were collected at MPM diagnosis, surgery or relapse. All patients gave inform consent, and the
study was approved by the Ethical Committee Zürich (ethical approval number: EK-ZH 2015-2171).
After collection, tissues were immediately placed in RNAlater solution (Qiagen, Hombrechtikon,
Switzerland) for preservation of the RNA integrity. Fresh tumor tissues harvested from the in vivo
experiment were immediately placed in liquid nitrogen and stored at −80 ◦C until analysis.
4.4. RNA Extraction, cDNA Synthesis and Quantitative Real-Time PCR
We employed a TRIzol reagent (Invitrogen 15596018, Life Technology Europe BV, Zug, Switzerland),
using the protocol suggested by the manufacturer, for RNA extraction. We used PrimeScript RT with
gDNA Eraser (TAKARA Bio, S-86901-06-01, Saint-Germain-en-Laye, France,) for cDNA synthesis and
KAPA SYBR FAST qPCR master mix with ROX (Kapa Biosystems, KK4621 Merck, Buchs, Switzerland)
for quantitative real-time PCR with a 7500 real-time PCR system (Life technology, Life Technology
Europe BV, Zug, Switzerland). For MPM, only specimens containing >50% tumor contents were
selected for the analysis. We estimated tumor contents by analyzing gene expressions of calretinin,
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mesothelin and podoplanin normalized against histone RNA, as previously described [38]. A list of
primers is provided in Table S3.
4.5. Cell Lines
Mero-83, Mero-84, Mero-41, Mero-14, Mero-25, Mero48a, Mero-82, NO36 and ONE58 were
obtained from the European Collection of Cell Cultures (Salisbury, UK). ACC-Meso-1 and ACC Meso-4
were purchased from Riken BRC (Ibaraki, Japan). Met5A and MSTO211H cell lines were from ATCC
(Wesel, Germany). Dr. Emanuela Felley-Bosco kindly provided ZL55 and SDM104 [18]. All cell lines
were maintained in RPMI1640 with ATCC modification (Gibco, A10491-01 Life Technology Europe BV,
Zug, Switzerland,), supplemented with 10% fetal bovine serum (FBS) and penicillin/streptomycin (p/s).
All cell lines were regularly tested for mycoplasma contamination.
4.6. Treatment and Cell Survival Analysis for 2D and 3D Culture
For 2D cultures, cell lines were seeded with 3000 cells/well in a 96-well plate. Twenty-four hours
later, cells were treated with different concentrations of pevonedistat (2-fold dilutions, ranging from
0.039 to 5 µM) in their complete medium. At 72 h after the treatment, cell survival was measured by
3-(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide (MTT) assay. Briefly, cells were exposed
to 1-mg/mL MTT solution (3-(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide) in Dulbecco’s
modified Eagle’s medium (DMEM)/F12 medium without phenol red plus 0.5% FBS for 90 min,
followed by cell lysis in a solution containing 50% dimethylformamide (DMF) and 20% sodium dodecyl
sulfate (SDS) pH 4.7 and optical density (OD) measurement at 570 nm.
4.7. Protein Extraction and Western Blot
We used radioimmunoprecipitation assay (RIPA) buffer containing a proteinase and phosphatase
inhibitor cocktail (Cell Signaling, #5872, Danvers, MA, USA) for cell lysis for 20 min, followed by DNA
shearing by sonication. The following antibodies were used for Western blot experiments: CUL4A,
Cell Signaling, Danvers, MA, USA, CUL4B, Sigma HPA011880, Buchs, Switzerland, actin, Santa Cruz
I19, Heidleberg, Germany, tubulin, Abcam ab6046 Cambridge, UK, CDT1, Cell Signaling, Danvers, MA,
USA, p21 BD Bioscience, San Jose, CA, USA, cleaved caspase-3, Cell Signaling, Danvers, MA, USA,
and phospho-histone H3 (Ser10) (pH3), Cell signaling, Danvers, MA, USA. Western blot imaging and
signal quantification was performed using Fusion FX7 (Witec AG, Sursee, Switzerland). Uncropped
blots with molecular weight markers are provided as Figure S7.
4.8. Cell Cycle Analysis
The treatment with pevonedistat was performed in a cell culture medium for 24 h. Following
fixation with methanol, cells were permeabilized with 0.25% TritonX-100 and subjected to staining
with anti-pH3 antibody (Cell Signaling, Danvers, MA, USA; diluted 1:50 in 5% bovine serum
albumin (BSA)/0.2% Triton/phosphate-buffered saline (PBS)). Secondary antibody was goat anti-rabbit
Alexa488-conjugated antibody (Invitrogen, A11034, Life Technology Europe BV, Zug, Switzerland),
followed by co-staining with propidium iodide (PI). Data were acquired by a flow cytometer (Attune,
Applied Biosystems, Life Technology Europe BV, Zug, Switzerland) and analyzed by FlowJo software
v.10 (BD Biosciences, San Jose, CA, USA).
4.9. MPM Spheriod Cultivation, Treatment and Viability Measurement
To prepare a nonadherent concaved surface for spheroid formation, 96-well cell culture plates were
filled with 50-µL melted sterile agarose. A different starting cell seeding number in RPMI 1640 with
ATCC modification supplemented with 10% FBS and (P/S) was used to achieve a spheroid diameter
of 370–400 µm on day 4 after seeding [39]. Spheroids were treated with different concentrations of
pevonedistat (2-fold dilution ranging from 0.312 to 2.5 µM) or cisplatin (2-fold dilution ranging from 2.5
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to 20 µM) in the full culture medium on day 4 after seeding and refreshed on day 7. We monitored the
drug efficacy by measuring the spheroid diameter on days 4 (before the treatment), 7, 9 and 11 (Axiovert
40 CFL (Zeiss, Oberkochen, Germany)). At the endpoint on day 11, we measured the cell viability by
acid phosphatase (APH) assay [40]. Briefly, spheroids were washed with Dulbecco’s phosphate-buffered
saline DPBS; afterwards, 100 µL of 2-mg/mL p-nitrophenyl phosphate, disodium salt, hexahydrate
(PNPP) (Thermo scientific, 34045, Life Technology Europe BV, Zug, Switzerland) in 0.1-M sodium
acetate, 0.1% Triton X-100/water were added to a spheroid in 100-µL D-PBS. After 90 min incubation,
we added 10-µL 1-N NaOH to stop the enzymatic reaction. The change in pH to alkaline resulted in
p-nitrophenol turning yellow, which was measured at 405 nm within 10 min.
4.10. Immunofluorescence
Frozen tumor tissues or spheroids embedded in optimal cutting temperature (OCT) medium were
cryosectioned into 10 µm and air-dried. For CDT1 staining, slides were fixed in Delaunay fixative
and air-dried. Slides were rehydrated, fixed with 4% paraformaldehyde, permeabilized with 0.2%
triton X-100 in PBS and blocked with 4% BSA, 5% normal serum and 0.1% Tween in PBS. We used the
following antibodies diluted in 2% BSA, 2.5% normal serum in PBS, 0.1% Tween: pH3 (Abcam, ab5176,
Cambridge, UK, 1:200), Cl.C3 (Cell signaling, Danvers, MA, USA, 1:400), pan-cytokeratin (Abcam,
ab86734, Cambridge, UK, 1:300), CDT1 (Abcam, Ab202067, Cambridge, UK, 1:50), goat anti-rabbit
IgG Alexa 488 (Thermo Scientific, A11008, Life Technology Europe BV, Zug, Switzerland, 1:500)
and donkey anti-mouse IgG Alexa 555 (Thermo Scientific, A31570, Life Technology Europe BV, Zug,
Switzerland, 1:500). We used an additional blocking step with anti-mouse IgG for the staining on mouse
tissues (Thermo Scientific, A16074, Life Technology Europe BV, Zug, Switzerland, 1:25). Images were
acquired by a Leica DM6000 (Leica Microsystems, Heerbrugg, Switzerland). We counted tumor cells
(pan-cytokeratin+) positive for pH3 and Cl.C3 manually, and all tumor cells were quantified for CDT1
intensity using Image J 1.52a (Madison, WI, USA) software in at least 900 tumor cells.
4.11. Animal Experiment
The animal experiment was performed according to the regulation of the Veterinary Office of the
Canton, Zurich, Switzerland. Six-to-8-week-old male Fox Chase severe combined immunodeficiency
(SCID) mice (CB17/Icr-Prkdcscid/IcrIcoCrl; IcrIcoCrl, Charles River, Sulzfeld, Germany) were housed
according to the guidelines for animal welfare. We randomized mice into 4 groups (ACC-Meso-1 control
and -treated, and MSTO211H control and -treated) after at least 2 weeks’ adaptation. Tumor implantation
by intraperitoneal injection (i.p.) was performed on day 0 (21 days before the treatment start for mice
receiving Meso-1 and 12 days before the treatment start for MSTO211H). We implanted 5 × 106 cells
ACC-Meso-1 or 1 × 106 cells MSTO211H in 200-µL sterile DPBS. Both cell lines were authenticated and
tested to be free from rodent and human pathogens, as well as mycoplasma. Pevonedistat (Active
Biochem, Kowloon, Hong Kong) was freshly prepared in sterile 3.33% dimethylsulfoxide (DMSO)
and 20% cyclodextrin in water with a concentration of 10 mg/mL. Mice were treated twice-daily
(BID) i.p. with pevonedistat for 3 cycles of 5 days’ treatment with 5 days’ treatment-free period;
see Figure 5a. We had to increase the dosage gradually during the first treatment cycle due to weight loss
of MSTO211H tumor-bearing mice if they were immediately treated with a high dose. Administration
of a high dose in the second and third cycles was tolerated in both groups (see body weight changes
in Figure S5). Mice were monitored daily and blindly after tumor implantation until the end of the
experiment for signs of pain and distress, changes in activity, body weight, body condition score [41]
and ascites formation. In case of impaired health status measured by the previously mentioned criteria,
they were humanely euthanized, and the time from tumor cell implantation to time of euthanasia
was considered as the overall survival. To analyze the changes in tissues following the treatment,
mice were treated with 1 cycle of pevonedistat; tumor tissues were excised and immediately preserved
for further analyses.
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4.12. Statistical Analyses
We used SPSS v.25 (IBM, New York, NY, USA) for survival analysis of the MPM patient cohort
and GraphPad Prism v.8.0.0 (San Diego, CA, USA) for Mann Whitney, t-tests, IC50 calculation and
survival analysis of the in vivo experiments.
5. Conclusions
Although a relatively rare disease, MPM is fatal and difficult to treat. The standard of care treatment
still relies on DNA-damaging agents and antimetabolite-like cisplatin and pemetrexed. Although
the lack of oncogenic driver hinders the development of targeted treatment for MPM, deciphering
pathway alterations resulting from tumor-suppressor gene loss may shed light on additional key
molecules that can serve as a treatment target for MPM. Previous studies have shown that CUL4
ubiquitin ligase complex is one of the pathways being unleashed when the key tumor suppressor
for MPM, NF2, is mutated. Here, we discovered that CUL4 paralogs CUL4A and CUL4B were also
upregulated in MPM and a high expression of CUL4B correlated with the worst prognosis, underlying
the importance of CUL4 ubiquitin ligase in MPM. Thus, alterations of the ubiquitination event may be
one of the key factors driving mesothelioma, and this is emphasized by the fact that another tumor
suppressor frequently mutated in MPM, BRCA1-associated protein-1 (BAP1), also functions as a
nuclear deubiquitinating enzyme. Thus, it is important to investigate in more detail regarding the
mechanisms of CUL4B upregulation and how the overexpression drives MPM progression. A subset
of MPM cell lines are sensitive to pevonedistat, a small molecule that inhibits all cullins by targeting
protein neddylation. Interestingly, the treatment also induced a tumor response by targeting the
immune microenvironment, which may provide additional favorable clinical benefits. Nevertheless,
pevonedistat has a broad spectrum of targets, as all cullins and some other proteins like p53 are also
regulated by neddylation. Therefore, identifying a targeted agent that is specifically acting on CUL4B
or its complex may further improve the clinical benefits and minimize the undesirable side effects.
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